### **Overview** Alkem Laboratories Ltd. is a leading Indian pharmaceutical company with over 50 years of operations, headquartered in Mumbai. As of November 2025, the company ranks as the **5th largest pharmaceutical player in India by market share**, with a strong global footprint across more than 40 countries. It operates across a diversified portfolio encompassing **branded generics, complex generics, biosimilars, APIs, nutraceuticals, and medical devices**. With a presence in high-growth markets such as the United States, Latin America, Australia, and Europe, Alkem continues to expand both organically and through strategic acquisitions. The company generated over ₹125 billion in global revenue during FY2024 and is listed on the NSE and BSE. Its strategic vision focuses on **sustainable growth, innovation, chronic therapy leadership, and digital transformation** across global operations. --- ### **Key Business Segments & Therapeutic Strengths** #### **1. Acute Care Leadership** Alkem maintains dominant market leadership in **acute therapy segments**, particularly: - **Anti-infectives** (market leader for over 15 years) - **Gastrointestinal (GI)** disorders - **Pain management** - **Vitamins, Minerals & Nutrients (VMN)** Flagship brands such as **Clavam, Pan, Pan-D, Taxim-O, A to Z**, and **Uprise D3** are ranked among India’s top 50 pharmaceutical brands, with multiple brands in the top 100 and top 300. The PAN brand family alone is the largest in the GI segment and entered the top 5 of IPM rankings. #### **2. Chronic Therapy Expansion – Strategic Priority** Chronic disease management is a core growth driver for Alkem, reflecting rising lifestyle diseases and patent expirations in high-value molecules. - Chronic therapies now contribute **~17–18% of domestic revenue**, with a strategic goal to reach **20% of total revenues**. - Outperformed market growth in: - **Anti-diabetics**: Grew at ~16% (vs. market at ~5%), achieving 23% CAGR (FY20–FY24) - **Neuro/CNS**: #6 in India; growing more than 2x the market - **Dermatology**: Launched differentiated products (e.g., Clindac, Kojiglo, Olesoft) backed by clinical evidence - **Respiratory**: Expanded inhalation therapies with Pulmicaps and Innohaler technology **Notable Chronic Care Brands:** - **Dapanorm (Dapagliflozin)**: Now the leader in empagliflozin SKUs post-patent expiry (Mar 2025) - **Dapanorm Trio**: Among the fastest-growing antidiabetic launches; became #1 in its category - **Glucoryl**: ₹1+ billion brand in diabetes --- ### **Oncology & Biosimilars – Innovation Engine** Oncology is a **strategic priority** for Alkem, led by its biologics subsidiary **Enzene Biosciences Limited**. Key developments: - **Launched Pertuza (Pertuzumab biosimilar)** in India (Sep 2025): First indigenously developed, affordable version for **HER2-positive breast cancer**. - Demonstrated **equivalence to reference product** in a Phase 3 trial. - Aims to improve access in price-sensitive markets. - **Cetuxa**: World’s first biosimilar of **Cetuximab** (for head & neck cancer). - Enzene has **commercialized 7 biosimilars** in India, including **Bevacizumab, Denosumab, Romiplostim**, and **Adalimumab**. - Pipeline includes **Pertuzumab (India launch FY2026), Semaglutide (Mar 2026 expiry), and Nivolumab (May 2026)**. **Enzene’s Capabilities:** - **“Clone to Vial” Biologics CDMO (Contract Development & Manufacturing Organization)** platform - Proprietary **EnzeneX™**: First globally to implement **end-to-end continuous manufacturing** for biologics - 10x higher productivity - 50% lower carbon footprint - Smaller footprint, faster scale-up, lower costs - Global manufacturing: - **Chakan (Pune), India**: Bioreactor capacity 20–2,000 L with single-use tech and fill-finish line. EMA-ready. - **New Jersey, USA**: Clinical production began Mar 2025; full-scale operations expected by mid-FY2026. --- ### **Medical Devices – Alkem MedTech** A major strategic pivot into **high-growth orthopedic implants** via **Alkem MedTech Pvt. Ltd.**, established in FY2025. - Focused on **knee and hip joint replacement implants**, representing ~65% of the ₹4,000 crore Indian orthopedic market. - **Acquired Bombay Ortho (₹147 crore)**: Gained end-to-end manufacturing, production capacity (~2,000 joints/month), and domestic market entry. - **Technology Transfer & Licensing with Exactech (US)**: Rights to manufacture and market premium knee & hip implants in India, including **trademark rights**. - **Rajkot Facility**: ISO 13485 & EU MDR compliant; scalable to triple output in 12 months. - **Indigenous Instrument Development**: Supporting “Make in India” and import substitution. - Strategic collaborations with **Indian hospitals** for **Real-World Evidence (RWE)** and **Post-Market Surveillance (PMS)**. - Expansion plans into **shoulder implants and sports medicine**. - Investments in automation, robotics, and **SAP digital transformation** for end-to-end integration. --- ### **Global Markets & International Strategy** | Market | Revenue Contribution (FY2025) | |----------------|-------------------------------| | **India** | ~70% (₹89,837 million) | | **USA** | ~19.4% | | **RoW** | ~10.4% (₹13,392 million) | #### **U.S. Operations** - ~22% of total revenue; over $200 million annual run-rate. - Focus on **niche, complex generics** (injectables, peptides, complex oral formulations) to de-risk pricing pressures. - Filed **185 ANDAs & 2 NDAs** with USFDA; **156 ANDAs approved** (13 tentative), including **Marinol (Dronabinol)**. - Previously scaled back on authorized generics and closed the St. Louis facility due to regulatory and commercial challenges. - Strategy: **First-to-market and Para IV filings** for selective launches; pursue innovation over commoditization. #### **Rest of World (RoW) – High-Growth Focus** - Grew **8.7% YoY** (FY2025), driven by Australia, Latin America (Chile), and Europe (UK, Germany). - Filing **>700 dossiers in EU and LATAM**; over **1,100 product registrations** globally. - **“String of Pearls” strategy**: Targeted launches (~30 planned for FY2026) and organic expansion in high-potential emerging markets. - Acquired **Pharmacor SPA (Chile)** to strengthen LATAM footprint. --- ### **Research, Innovation & R&D Capabilities** - **6–7 R&D centers** across India and the US, staffed with **>500 scientists**. - Filed **185+ ANDAs, 2 NDAs with USFDA**, and **>1,100 dossiers internationally**. - Advanced drug delivery platforms: - **R AFT** – Gastro-floating gel barrier for acid reflux - **GRDS** – Gastro-retentive drug system - **Pulmicaps** – Dry powder inhalers with dose counters - **SNEDDS** – Enhanced bioavailability via self-nanoemulsification - **Effervescent tech** – For geriatric dosing - Strategic academic partnerships: - **Harvard University** (regenerative medicine for diabetic foot ulcers) - **Johns Hopkins University** (colorectal cancer therapy targeting angiogenesis) - **NIH, IIT Bombay, Tata Memorial, Biosergen (Sweden)** --- ### **Sales, Marketing & Digital Transformation** - **Field Force**: **~12,500 medical representatives** – second largest in India. - **Garnet 360** & **MediSamvad**: Digital platforms enabling real-time data, e-detailing, and clinician engagement. - **Project Aspire**: Performance intelligence engine for sales insights and effort tracking. - AI integration in **pharmacovigilance, regulatory submissions, and compliance**. - Launched **>75 new drugs in 2 years**, with **strong focus on post-patent generic launches**. --- ### **Manufacturing & Operations** - **19 global manufacturing facilities** (18 in India, 1 in USA), all approved by USFDA, WHO, MHRA, TGA, etc. - Dedicated API unit in **Mandva**, formulation units in **Taloja, Daman, Baddi**, and **Rajkot (MedTech)**. - Alkem Activa: Rebranded API vertical focused on global supply. - Trade Gx (Generic) segment: Market leader in India; contributes ~20% of domestic revenue. Over 3,000 authorized stockists and >950 field staff (planned). - **OTC Leadership**: Holds 50%+ in digestive remedies, 85%+ in analgesics OTC, 80%+ in smoking cessation. --- ### **Acquisitions & Strategic Diversification** Alkem is actively expanding into adjacent high-growth sectors: | Acquisition | Date | Focus | Value | |-----------|------|--------|--------| | **Adroit Biomed** | FY2025 | Dermatology-cosmetology | ₹140 crore | | **Bombay Ortho** | FY2025 | Orthopedic implants | ₹147 crore | | **Pharmacor (Australia)** | 2009 | International platform | — | | **Ascend Labs (USA)** | 2010 | US market entry | — | | **Enzene Biosciences** | 2011 | Biosimilars platform | — | - Plans to invest **₹2,500 crore in MedTech** over 3–4 years. - Maintains **₹4,700 crore cash balance** for M&A in branded Rx and MedTech.